Replies to post #180525 on Biotech Values

[DewDiligence]

AGN makes small acquisition:

http://finance.yahoo.com/news/allergan-acquires-liris-program-taris-203000289.html

Allergan Inc. and TARIS Holdings LLC today announced that Allergan has closed a transaction to acquire worldwide rights to TARIS Biomedical’s lead program, LiRIS, which is currently in Phase 2 trials for the treatment of interstitial cystitis / bladder pain syndrome.

Allergan paid $67.5 million in cash upfront, subject to certain adjustments and holdbacks. Allergan has also agreed to pay up to an aggregate of $295 million in development milestone payments and up to an aggregate of $225 million in commercial milestone payments.

It will take more than this for AGN to fend off the hostile offer from VRX.